The European Union Aviation Safety Agency (EASA) and European Centre for Disease Prevention and Control (ECDC) issued an update to the health safety measures for air travel, paving the way for a relaxation of the need to wear medical masks on board a flight, but noting that a face mask is still one of the best protections against the transmission of COVID-19.
A continuous high incidence or a large surge in cases in the early summer would imply a large benefit from an early second booster roll-out but optimal timing will largely depend on trends in infections ECDC says in the latest technical report on a second mRNA COVID-19 vaccine booster dose.
European Immunization Week is marked across Europe every year in the final week of April. It aims to raise awareness of the importance of immunization for the general health and wellbeing of the European and wider population.
EMA and ECDC have reviewed currently available studies and epidemiological data to provide a common position for EU/EEA countries on the current need and potential benefit of a fourth dose (second booster dose) of mRNA COVID-19 vaccines.
ECDC and EMA’s COVID-19 task force (ETF) have concluded that it is too early to consider using a fourth dose of mRNA COVID-19 vaccines (Pfizer’s Comirnaty and Moderna’s Spikevax) in the general population.
According to the latest ECDC/WHO report on tuberculosis (TB) surveillance and monitoring in Europe, a sharp drop (24%) in reported tuberculosis cases between 2019 and 2020 was probably exacerbated by the COVID-19 pandemic, which hindered detection and reporting.
Displaced people from Ukraine hosted in reception centres should be offered free access to SARS-CoV-2 testing and vaccination for COVID-19. Additionally, protective measures are recommended by ECDC in the report Guidance for the prevention and control of COVID-19 in temporary reception centres in the context of the displacement of people from Ukraine, published on 18 March.
As of 30 January 2022, 70.9% of adolescents aged 15-17 years and 34.8% of 10-14 year-olds completed the primary course of COVID-19 vaccination, though with a broad range across EU/EEA countries. More than half of adolescents aged 10 to 17 in the EU/EEA have not yet completed a primary course.